open innovation system in Iran's biopharmaceutical industry

Siadati, Hadi; Ghazinoory, Sepehr; Fatemy, Mehdi

open innovation system in Iran's biopharmaceutical industry

Document Type : Qualitative Research

Authors

hadi siadati ¹

Sepehr ghazinoory ²

mehdi fatemy ³

¹ azad

² Tarbiat modares

³ Tarbiat Modares

Abstract

The biopharmaceutical industry in Iran is developing in parallel with the global trend. Given the risks and costs of research, development, production, and sales of these drugs, firms have moved toward open innovation models across different value chains in the last decade. However, the limited use of technological cooperation methods by the Iranian firms will trap the industry in genericization soon. Accordingly, the development of an open innovation system in the value chain of the Iranian biopharmaceutical industry provides the possibility of continuous development of the industry. In the present study, first, the technological capabilities of the firms in the Iranian biopharmaceutical industry were evaluated, and then some cases of technological cooperation in the industry were studied deeply. Accordingly, considering the "strategic" level of technological capability of firms and also the lessons learned from the multicase study of the experiences of the Iranian pharmaceutical firms, strategies including the completion of the value chain links, the use of export development tools, the supporting of the commercialization in universities and research institutes, the facilitation of technology integration and acquisition and finally the development of smart public financial support to develop are proposed for the development of open innovation system in the Iranian biopharmaceutical industry.

Keywords

innovation

technological cooperation

Open innovation

biopharmaceutical industry

20.1001.1.23222115.1400.12.4.7.9

Subjects

Pharmaceutical Biotechnology

1- Yadoollahi Farsi J, Kalanhaei Z. Technology exploitation mechanisms in biotechnology. Roshd-e-Fanavari Journal of Science & Technology Parks and Incubators. 2012; 8(3):62-70. [Persian]
2- Hamidi Motlagh R., Isaai M., Babaee A. embeddedness of state-pioneer entrepreneurs and technological change; the case of biopharmecutal catch-up in Iran. Journal of Science and Technology Policy, 2016; 9(4): 1-18. [Persian]
3- Saber A, Elahi S, Majidpour M., Shayan A, Sahebkar khorasani, S. Investigating the technological catch-up efforts in biopharmaceutical firms of Iran. Journal of Science and Technology Policy, 2018; 11(4): 49-63. [Persian]
4- Tabatabaeian S, Tahoori H, Taghva M, Taghavi Fard S. Analysis of innovation ecosystem of Iranian biopharmaceuticals. Journal of Technology Development Management, 2018; 6(1): 9-45. [Persian]
5- Taslimi M, Naghavi M., Mokhtarzadeh N, Babaei A. The role of intermediary institutions in the emergence of biopharma industry in Iran. Journal of Science and Technology Policy, 2018; 11(3): 29-44. [Persian]
6- Afshari Mofrad M, Salim A. Iranian firms in biopharmaceutical value chain: Where to go now?. Journal of Science and Technology Policy Management. 2019 Jun 12; 11(1): 49-63.
7- Chesbrough H, Vanhaverbeke W, West J, editors. Open innovation: Researching a new paradigm. Oxford University Press on Demand; 2006 Aug 10.
8- Enkel E, Gassmann O, Chesbrough H. Open R&D and open innovation: Exploring the phenomenon. R&D Management. 2009 Sep;39(4):311-6.
9- Goodarzi M, Goodarzi M. Review of Commercialization process of biopharmaceuticals: Lessons for Iran’s drug industry. Rahyaft, 2014; 24(1): 35-53. [Persian]
10- Radfar R, Pilevari N, Ghazinoory, SS, Shakeri, R. Study of firm-level strategic alliances drivers; case study Pharmaceutical industry. Management Researches, 2015; 8(27): 45-70. [Persian]
11- Bogers M, Chesbrough H, Moedas C. Open innovation: Research, practices, and policies. California management review. 2018 Feb;60(2):5-16.
12- Chesbrough H. Managing open innovation. Research-Technology Management. 2004 Jan 1;47(1):23-6.
13- Khaleghi, M., Elyasi, M. The new approach of open innovation: Basic concepts, literature and horizons ahead. Journal of Technology Development, 2016; 14(28): 87-100. [Persian]
14- Siadati H, Mofrad MA. Policies for promoting open innovation. Journal of Science and Technology Policy. 2019;11(2):379-393. [Persian]
15- Marques JP. Closed versus open innovation: Evolution or combination?. International Journal of Business and Management. 2014 Feb 1;9(3):196.
16- Chesbrough HW. Open innovation: The new imperative for creating and profiting from technology. Harvard Business Press; 2003.
17- Safdari Ranjbar M, Manteghi M, Tavakoli G. Open innovation: A comprehensive view on concepts, approaches, trends and key success factors. Roshd-e-Fanavari Journal of Science & Technology Parks and Incubators. 2014;10(40):45-65. [Persian]
18- Pajohesh Jahromi, A. Taxonomy of Open Innovation. Rahyaft, 2019;29(73):1-12. [Persian]
19- Chiesa V, Manzini R. Organizing for technological collaborations: a managerial perspective. R&D Management. 1998 Jul;28(3):199-212.
20- Majidpour M, Mojiri F. The evolution of the concepts and policies of international technology transfer. Journal of Science and Technology Policy, 2019;11(2):425-437. [Persian]
21- Harwood, R. The Open Innovation Methods Matrix. 100 open. 2016. accessed through https://www.100open.com/the-open-innovation-methods-matrix-part-1/
22- Van der Zee F, Rehfeld D, Hamza C. Open innovation in industry, including 3D printing. Study for the European Parliament. 2015.
23- Schuhmacher A, Germann PG, Trill H, Gassmann O. Models for open innovation in the pharmaceutical industry. Drug Discovery Today. 2013 Dec 1;18(23-24):1133-7.
24- Michelino F, Lamberti E, Cammarano A, Caputo M. Measuring open innovation in the Bio‐Pharmaceutical industry. Creativity and Innovation Management. 2015 Mar;24(1):4-28.
25- Raja, B. H. Open innovation in pharmaceutical industry: A case study of Eli Lilly. M.Sc. Thesis in KTH University, Sweden. 2015.
26- Bianchi M, Cavaliere A, Chiaroni D, Frattini F, Chiesa V. Organisational modes for open innovation in the bio-pharmaceutical industry: An exploratory analysis. Technovation. 2011 Jan 1;31(1):22-33.
27- Chiaroni D, Chiesa V, Frattini F. Investigating the adoption of open innovation in the bio‐pharmaceutical industry. European Journal of Innovation Management. 2009 Jul 31.
28- Munos B. Lessons from 60 years of pharmaceutical innovation. Nature Reviews Drug Discovery. 2009 Dec;8(12):959-68.
29- Sabatier V, Mangematin V, Rousselle T. Orchestrating networks in the biopharmaceutical industry: Small hub firms can do it. Production Planning and Control. 2010 Mar 1;21(2):218-28.
30- Mazzola E, Bruccoleri M, Perrone G. Open innovation and firms performance: State of the art and empirical evidences from the bio-pharmaceutical industry. International Journal of Technology Management. 2016;70(2-3):109-34.
31- Hu MC, Hung SC. Taiwan's pharmaceuticals: A failure of the sectoral system of innovation?. Technological Forecasting and Social Change. 2014 Oct 1;88:162-76.
32- Xia T, Roper S. From capability to connectivity—Absorptive capacity and exploratory alliances in biopharmaceutical firms: A US–Europe comparison. Technovation. 2008 Nov 1;28(11):776-85.
33- Hu Y, McNamara P, McLoughlin D. Outbound open innovation in bio-pharmaceutical out-licensing. Technovation. 2015 Jan 1;35:46-58.
34- Östlund U, Kidd L, Wengström Y, Rowa-Dewar N. Combining qualitative and quantitative research within mixed method research designs: a methodological review. International journal of nursing studies. 2011 Mar 1;48(3):369-83.
35- Creswell JW, Clark VLP, Gutmann ML, Hanson WE. Advanced Mixed methods Research Designs. In Handbook of mixed methods in social & behavioral research. Sage.
36- Rush H, Bessant J, Hobday M, Hanrahan E, Medeiros MZ. The evolution and use of a policy and research tool: assessing the technological capabilities of firms. Technology Analysis & Strategic Management. 2014 Mar 16;26(3):353-65.
37- Kale D, Little S. From imitation to innovation: The evolution of R&D capabilities and learning processes in the Indian pharmaceutical industry. Technology Analysis & Strategic Management. 2007 Sep 1;19(5):589-609.